In line, high doses of infliximab, a chimeric monoclonal antibody to TNF-α, increased the combined risk of death from any cause or hospitalization for heart failure (hazard ratio = 2.84) in patients with moderate-to-severe heart failure [141]. Here, TNF is linked to heart failure.